GSK
GSK plc
NYSE: GSK · London · Healthcare
$50.75-0.46 (-0.90%)Closed
Market Cap$219.01B
Cash—most recent
Runway—
P/E (TTM)—
52-Wk Range$41.76 – $59.60
Avg Volume4.5M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$50.75+45.6%
Pipeline

Drug candidates sponsored by GSK · ClinicalTrials.gov

67 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Duac® Gel / Differin® Gel
Acne Vulgaris
Completed
2005-08past
1
Phase 4Clobetasol propionate foam
Psoriasis
Completed
2007-12past
1
Phase 4Benzoyl peroxide with clindamycin
Acne
Completed
2008-08past
1
Phase 4Duac
Acne
Completed
2008-11past
1
Phase 4clobetasol propionate
Hand Dermatosis
Completed
2009-01past
1
Phase 4Epiduo Gel
Acne Vulgaris
Completed
2009-04-24past
1
Phase 4Olux-E Foam
Plaque-Type Psoriasis
Completed
2009-06past
1
Phase 4BENZOYL PEROXIDE/ CLINDAMYCIN
Acne Vulgaris
Completed
2009-06past
1
Phase 4Clindamycin and benzoyl peroxide
Acne Vulgaris
Completed
2009-08past
2
Phase 4Clindamycin and BPO 5% gel
Acne Vulgaris
Completed
2009-09past
1
Phase 4Clindamycin and benzoyl peroxide gel (Duac® Topical Gel)
Acne Vulgaris
Completed
2009-11past
1
Phase 4MAXCLARITY II (2.5% BPO) Foam Cleanser
Acne Vulgaris
Completed
2009-11-20past
1
Phase 4Unnamed
Acne Vulgaris
Completed
2009-12past
1
Phase 4Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene
Acne Vulgaris
Completed
2010-04past
1
Phase 40.25 % Miconazole Nitrate Ointment
Diaper Rash
Completed
2010-12past
1
Phase 4clobetasol propionate 0.05%
Dermatitis, Chronic
Completed
2011-03-01past
1
Phase 4Belimumab plus Early Vaccination
Systemic Lupus Erythematosus
Completed
2015-09-01past
1
Phase 4Placebo plus standard therapy
Systemic Lupus Erythematosus+1 more
Completed
2019-07-25past
2
Phase 2Liarozole
Ichthyosis, Lamellar
Completed
2007-04past
1
Phase 3U0267 Foam
Psoriasis
Completed
2008-10past
1
Phase 3Itraconazole 100mg capsules
Onychomycosis
Completed
2008-10past
1
Phase 3CT Gel
Acne Vulgaris+1 more
Completed
2009-04past
1
Phase 3CTGel/ BPO Wash
Acne Vulgaris
Completed
2009-06-01past
1
Phase 3Retpamulin Ointment, 1%
Skin Infections, Bacterial
Completed
2010-07past
1
Phase 3Tazarotene foam
Acne Vulgaris
Completed
2010-11-01past
4
Phase 3Calcipotriene Foam
Psoriasis
Completed
2010-12past
1
Phase 3alitretinoin
Eczema+1 more
Completed
2014-03-12past
2
Phase 3Belimumab 1 mg/kg
Systemic Lupus Erythematosus+1 more
Completed
2015-03past
2
Phase 3Dutasteride
Alopecia
Completed
2016-03-19past
1
Phase 3belimumab
Systemic Lupus Erythematosus+1 more
Completed
2016-12-09past
3
Phase 3Placebo
Systemic Lupus Erythematosus+4 more
Completed
2017-02-06past
5
Phase 3Momelotinib
Primary Myelofibrosis (PMF)+8 more
Completed
2021-12-03past
4
Phase 3BLU-5937
Cough+2 more
Active, not recruiting
2026-06-10past
5
Phase 33APS
Alzheimer's Disease
Unknown—1
Phase 2NC-503 (Anti-amyloidotic (AA) Agent)
Secondary (AA) Amyloidosis+5 more
Completed—1
Phase 2Talarozole
Acne+2 more
Completed
2007-05-01past
3
Phase 2Benzoyl peroxide gel
Acne Vulgaris
Completed
2009-03past
1
Phase 2NC-503 (eprodisate disodium)
Diabetes Mellitus, Type 2+1 more
Completed
2010-01past
1
Phase 2SRT2104
Diabetes Mellitus, Type 2+1 more
Completed
2013-03-18past
2
Phase 1Mapatumumab
Carcinoma, Hepatocellular+1 more
Completed
2013-05-31past
2
Phase 2PNT2258
Lymphoma, Diffuse Large B-Cell+5 more
Completed
2016-08past
3
Phase 2MMB
Primary Myelofibrosis (PMF)+2 more
Completed
2017-07-18past
1
Phase 2RPT193
Atopic Dermatitis+1 more
Completed
2024-06-21past
3
Phase 1FLX475 (tivumecirnon)
Advanced Cancer
Completed
2024-12-31past
1
Phase 2NC-758 (Anti amyloidotic [Aß] agent)
Stroke+1 more
Completed—1
Phase 1Itraconazole
Healthy
Completed
2008-07past
1
Phase 1W0027
Tinea Pedis
Completed
2008-08past
1
Phase 1250 mg SRT2104 Suspension
Diabetes Mellitus, Type 2
Completed
2008-12-22past
1
Phase 1Albaconozole
Onychomycosis
Completed
2009-12-04past
1
Phase 1Tazarotene
Acne Vulgaris
Completed
2009-12-20past
1
Phase 1Albaconazole tablet 400mg
Onychomycosis
Completed
2010-01-20past
1
Phase 1Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,
Acne Vulgaris
Completed
2010-06-12past
1
Phase 1Tazarotene (Patch application in Challenge Phase)
Acne Vulgaris
Completed
2010-06-26past
1
Phase 1SRT3025
Diabetes Mellitus, Type 2
Completed
2011-11-24past
1
Phase 1SRT2379
Sepsis
Completed
2011-12-12past
2
Phase 1Cap SRT2104
Psoriasis
Completed
2012-12-05past
1
Phase 1GSK2894512 cream
Psoriasis
Completed
2014-07-02past
1
Phase 1S. sonnei 1790GAHB
Shigellosis
Completed
2015-04past
2
Phase 1Combination therapy GSK2894512 Cream A + GSK2894512 Cream B
Dermatitis, Atopic
Completed
2015-09-24past
1
Phase 1Momelotinib (MMB)
Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer+1 more
Terminated
2017-01-12past
2
Phase 1FLX925
Acute Myeloid Leukemia
Terminated
2017-05-03past
1
Phase 1[14C]-BLU-5937
Healthy
Completed
2020-09-23past
1
Phase 114C RPT193
Healthy Male Subjects
Completed
2023-10-12past
1
Phase 1BLU-5937 IR
Cough+1 more
Completed
2024-05-02past
1
Phase 1GSK5464714- Camlipixant
Cough
Completed
2024-08-22past
1
Phase 1Camlipixant
Cough+1 more
Completed
2024-12-17past
3
N/AUnnamed
Acne Vulgaris
Completed
2011-12-01past
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for GSK. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.